Turning Point Brands (TPB) Q4 2024 earnings summary

Executive summary

• FY2024 net sales rose 11% to $360.7 million, with adjusted EBITDA up 12% to $104.5 million and Q4 revenue up 13% to $93.7 million.

• Zig-Zag and Stoker's brands delivered strong performance, with Zig-Zag FY sales up 7% to $192.4 million and Stoker's up 16% to $168.3 million.

• Modern oral brands FRE and ALP showed significant growth, with FRE Q4 sales up 419% year-over-year and modern oral Q4 revenue at $11.2 million.

• The CDS segment was divested and is now classified as discontinued operations, impacting Q4 net income.

• Generated $56 million in free cash flow for FY2024, driven by internal initiatives and core business outperformance.

Financial highlights

• FY2024 gross margin was 55.9%, down 39 bps year-over-year; Q4 margin was 56%, down 108 bps.

• Adjusted EBITDA margin for FY2024 was 29.0%; adjusted EBITDA less CapEx margin was 27.7%.

• Q4 gross profit increased 10.6% to $52.4 million; FY gross profit up 10.2% to $201.6 million.

• SG&A for the year was $122.4 million, with $11.5 million in adjustments; Q4 SG&A was $34.5 million, including $2.9 million in restructuring and $1.1 million in transaction costs.

• Total gross debt at year-end was $248.6 million; net debt $202.4 million; liquidity $103.6 million.

Outlook and guidance

• FY2025 adjusted EBITDA guidance is $108–$113 million; modern oral brands expected to generate $60–$80 million in 2025 revenue.

• Management sees significant growth opportunities in white nicotine pouches, mass-market cigars, and alternative channels.

• CapEx for 2025 budgeted at $4–$5 million, with $3–$6 million allocated for modern oral PMTA regulatory support.

• Mid-single-digit growth projected for core business, excluding modern oral.